Discovery of 4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine, an Orally Active, Non-Nucleoside Adenosine Kinase Inhibitor
Authors:
- 26 May 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (13) , 2133-2138
Abstract
Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC50 = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC50 = 1.7 nM) non-nucleoside AK inhibitor with oral activity in animal models of pain and inflammation.Keywords
This publication has 4 references indexed in Scilit:
- Purinergic and pyrimidinergic receptors as potential drug targetsBiochemical Pharmacology, 2000
- Adenosine. The signal of life?Circulation, 1991
- Clitocine, a new insecticidal nucleoside from the mushroom clitocybe inversaTetrahedron Letters, 1986
- Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: Pharmacological activities and potent inhibition of adenosine kinaseBiochemical Pharmacology, 1984